Post

Risk adjusted net present value: What is the current valuation of Sanofi’s SAR-442970?

SAR-442970 is a monoclonal antibody commercialized by Sanofi, with a leading Phase II program in Hidradenitis Suppurativa. According to Globaldata, …

Risk adjusted net present value: What is the current valuation of Kymera Therapeutics’s KT-253?

KT-253 is a small molecule commercialized by Kymera Therapeutics, with a leading Phase I program in Acute Lymphocytic Leukemia (ALL, …

Risk adjusted net present value: What is the current valuation of Apogee Therapeutics’s APG-777?

APG-777 is a monoclonal antibody commercialized by Apogee Therapeutics, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema). …

Risk adjusted net present value: What is the current valuation of Pyxis Oncology’s PYX-201?

PYX-201 is a monoclonal antibody conjugated commercialized by Pyxis Oncology, with a leading Phase I program in Thyroid Cancer. According …

Risk adjusted net present value: What is the current valuation of Sanofi’s Lunsekimig?

Lunsekimig is a monoclonal antibody commercialized by Sanofi, with a leading Phase II program in Asthma. According to Globaldata, it …